| Identification | Back Directory | [Name]
1-((4-cyano-4-(pyridin-2-yl)piperidin-1-yl)methyl)-4-oxo-4H-quinolizine-3-carboxylic acid | [CAS]
1144504-35-7 | [Synonyms]
PQCA
1-((4-cyano-4-(pyridin-2-yl)piperidin-1-yl)methyl)-4-oxo-4H-quinolizine-3-carboxylic acid
4H-Quinolizine-3-carboxylic acid, 1-[[4-cyano-4-(2-pyridinyl)-1-piperidinyl]methyl]-4-oxo- | [Molecular Formula]
C22H20N4O3 | [MDL Number]
MFCD26403374 | [MOL File]
1144504-35-7.mol | [Molecular Weight]
388.42 |
| Chemical Properties | Back Directory | [Boiling point ]
708.5±60.0 °C(Predicted) | [density ]
1.41±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 10 mg/mL (25.75 mM; ultrasonic and warming and heat to 80°C) | [form ]
Solid | [pka]
1.83±0.20(Predicted) | [color ]
White to yellow |
| Hazard Information | Back Directory | [Uses]
PQCA is a highly selective and potent muscarinic M1 receptor positive allosteric modulator. PQCA is a novel M1 muscarinic potentiator that improves cognition without adverse effects compared to donepezil and xanomeline in rhesus monkey. | [in vivo]
PQCA (3-30 mg/kg; oral administration; single- or pair-housed male rhesus monkeys) treatment attenuates the scopolamine deficits in PAL and CPT tasks. Blockade of muscarinic signaling by scopolamine produces significant impairments in both tasks[1]. | Animal Model: | Ten single- or pair-housed male rhesus monkeys (6-10 years old; 5.2-10.5 kg) with scopolamine[1] | | Dosage: | 3 mg/kg, 10 mg/kg, or 30 mg/kg | | Administration: | Oral administration | | Result: | Attenuated the scopolamine deficits in paired-associates learning (PAL) and the continuous-performance task (CPT).
|
| [storage]
Store at -20°C |
|
|